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lished, illustrate that there is room for improvement regarding
choice of empiric antimicrobial treatment.
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OBJECTIVES: To estimate the indirect cost burden of migraine
on U.S. employers, in terms of workplace absence, short-term
disability (STD) and workers compensation (WC) payments.
METHODS: The data source for this study was the MEDSTAT
Health and Productivity Management database, composed of
medical, pharmaceutical, enrollment, workplace absence, STD,
and WC information on employees for 10 large employers in the
U.S. for the calendar years 2002 and 2003. Subjects with a diag-
nosis for migraine or use of a migraine-speciﬁc abortive drug
were identiﬁed as the migraine cohort. A random sample of
patients without migraine was propensity score matched, based
on demographic characteristics and comorbidity index, to the
migraine cohort to yield a matched control group. Indirect costs
between migraine and matched control cohorts were compared
to derive the indirect burden of illness attributable to migraine.
RESULTS: The analyses included 5037 subjects in the migraine
cohort, and equal number of subjects in the control group. The
mean age was 39 (SD = 9.3), and 71% were female. After match-
ing, the cohorts were similar with respect to age, gender, geo-
graphic region, urban residence, insurance type, the number of
psychiatric diagnostic groups and Charlson comorbidity index.
The migraine cohort incurred signiﬁcantly higher indirect costs
than the control cohort in all categories (absence, STD, and WC).
Total indirect costs were $2834 per patient per year (PPPY)
higher in the migraine group ($4453 versus $1619 PPPY in the
control group; p < 0.001). Absence costs made up the largest
component of this difference at 75%, with STD and WC making
up 21% and 4%, respectively. CONCLUSIONS: The migraine
cohort was associated with signiﬁcantly higher indirect costs
compared to a matched control based on recent data from a
sample of commercially insured individuals. This data suggest
that US employers are bearing a considerable indirect cost
burden as a consequence of migraine.
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OBJECTIVES: In a previously published study dose increases
have been shown to be signiﬁcantly more pronounced with trans-
dermal (TD) fentanyl compared to TD buprenorphine. The
purpose of this study was not only to re-evaluate these results
because of the high economic impact but also to qualitatively
evaluate the dose development as a measure of ease of dosing
and dose adjustment during therapy with TD fentanyl and TD
buprenorphine in cancer and non-cancer patients. METHODS:
Retrospective analysis of the German “IMS Disease Analyzer—
mediplus” database covering patient data from May, 2002 to
April, 2005. Patients on long-term treatment (≥3 months) with
TD fentanyl or TD buprenorphine had received similar analgesic
pre-medication and were considered as identical cohorts with
similar pain intensity, expecting comparable drug utilization pat-
terns. Dose changes over the treatment duration were evaluated
qualitatively and quantitatively. RESULTS: From dose changes
over the whole treatments mean daily dose increases per patient
were calculated to be 0.47% (TD fentanyl) and 0.19% (TD
buprenorphine) in cancer patients, and 0.25% and 0.10% in
non-cancer patients, respectively. Despite the overall dose
increases, qualitative evaluations revealed dose changes in both
directions, i.e. dose increases and decreases during therapy in
30.6% of TD fentanyl and 11.8% of TD buprenorphine patients
with cancer pain. In non-cancer pain 22.7% of TD fentanyl and
13.1% of TD buprenorphine patients had alternating dose
changes. All differences between TD fentanyl and TD buprenor-
phine were statistically signiﬁcant (p < 0.05). CONCLUSIONS:
The more pronounced dose increases with TD fentanyl in com-
parable pain patients conﬁrm previous ﬁndings, indicating a
higher tolerance development with TD fentanyl. Regardless of
the overall dose increases, alternating dose changes, i.e. changes
in both directions are more frequent with TD fentanyl. This also
suggests a less convenient and more complicated dose adjustment
with TD fentanyl compared to TD buprenorphine.
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OBJECTIVE: Insomnia is a common condition affecting millions
of people across the United States. Most often it occurs in con-
junction with other illnesses and is chronic in at least one-third
of its cases. Studies have shown insomnia to be an underre-
ported, underdiagnosed and undertreated problem. The purpose
of this study is to report the recent patterns of health services
and prescription use for insomnia among a state Medicaid pop-
ulation. METHODS: The design was a cross-sectional, descrip-
tive study using Medicaid administrative claims data from
calendar year 2003. Recipients with either a claim paid for a
medical service with a diagnosis of insomnia, or a prescription
claim with an NDC number for zolpidem, temazepam, estazo-
lam, triazolam, quazepam, ﬂurazepam, or zaleplon were
selected. Rates of medical services use were calculated based on
state recipient population ﬁgures for ﬁscal year 2002–2003.
Dollars paid were from the perspective of Medicaid. RESULTS:
There was a total sample of 13,161 recipients identiﬁed with
insomnia, at a rate of 36.9 per 1000 recipients. A substantial
majority of medical services utilization occurred in a physician
ofﬁce or outpatient clinic, with very few visits for this condition
occurring in the emergency department or inpatient setting. The
overall rate of ofﬁce/clinic visits was 22.4 per 1000 recipients.
The highest ofﬁce/clinic visit rates by demographic groups
occurred among recipients between 45 to 64 years of age (66.8
visits per 1000), females (22.5 visits per 1000), and whites (21.5
visits per 1000). The average cost per ofﬁce/clinic visit was
approximately $91. Among the prescription claims for drugs
approved to treat insomnia, roughly 98 percent were for 
zolpidem. This particular drug cost Medicaid approximately 
$65 per claim. CONCLUSION: Ofﬁce visit use for the treatment
of insomnia varied by demographic groups. Zolpidem was 
used more extensively than other drugs approved for this 
condition.
